M) in 2021. In this article, we will break down Chimerix as a potential position in addition to your existing holdings. We will inspect why it could be a game-changer for Chimerix investors. " name="Description" /> M) in 2021. In this article, we will break down Chimerix as a potential position in addition to your existing holdings. We will inspect why it could be a game-changer for Chimerix investors. " /> M) in 2021. In this article, we will break down Chimerix as a potential position in addition to your existing holdings. We will inspect why it could be a game-changer for Chimerix investors. " />

Are Chimerix (NASDAQ:CMRX) investors starting to hold back?

Chimerix Accrued Expenses Turnover is fairly stable at the moment as compared to the past year. Chimerix reported Accrued Expenses Turnover of 1.91 in 2020. Cash and Equivalents Turnover is likely to rise to 0.39 in 2021, whereas Net Income Per Employee is likely to drop (3.1 M) in 2021. In this article, we will break down Chimerix as a potential position in addition to your existing holdings. We will inspect why it could be a game-changer for Chimerix investors.
Published over a year ago
View all stories for Chimerix | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Ellen Johnson

Chimerix holds a performance score of 14 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.3393, which signifies possible diversification benefits within a given portfolio. Let's try to break down what Chimerix's beta means in this case. As returns on the market increase, Chimerix returns are expected to increase less than the market. However, during the bear market, the loss on holding Chimerix will be expected to be smaller as well. Although it is essential to pay attention to Chimerix historical returns, it is also good to be reasonable about what you can do with equity current trending patterns. Our philosophy towards foreseeing future potential of any stock is to look not only at its past charts but also at the business as a whole, including all available fundamental and technical indicators. To evaluate if Chimerix expected return of 2.07 will be sustainable into the future, we have found twenty-one different technical indicators, which can help you to check if the expected returns are sustainable. Use Chimerix semi deviation, jensen alpha, as well as the relationship between the Jensen Alpha and semi variance to analyze future returns on Chimerix.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Chimerix. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Chimerix

Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Chimerix's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Chimerix. Your research has to be compared to or analyzed against Chimerix's peers to derive any actionable benefits. When done correctly, Chimerix's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Chimerix.

Watch out for price decline

Please consider monitoring Chimerix on a daily basis if you are holding a position in it. Chimerix is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Chimerix stock to be traded above the $1 level to remain listed. If Chimerix stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is Chimerix's Liquidity

Chimerix financial leverage refers to using borrowed capital as a funding source to finance Chimerix ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Chimerix financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Chimerix's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Chimerix's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Chimerix's total debt and its cash.

A Deeper Perspective

The current price rise of Chimerix could raise concerns from investors as the firm it trading at a share price of 8.42 on very low momentum in volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in February. The stock standard deviation of daily returns for 30 days investing horizon is currently 10.15. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Chimerix partners.

Returns Breakdown

Return on Investment(95.21)
Return on Assets(0.71)
Return on Equity(0.78)
Return Capital(1.21)
Return on Sales(8.73)

Our perspective of the current Chimerix rise

Chimerix current downside deviation rises over 2.91. Chimerix is displaying above-average volatility over the selected time horizon. Investors should scrutinize Chimerix independently to ensure intended market timing strategies are aligned with expectations about Chimerix volatility.

While some firms under the biotechnology industry are still a bit expensive, Chimerix may offer a potential longer-term growth to investors. To sum up, as of the 9th of January 2021, we see that Chimerix slowly supersedes the market. The company is overvalued with very low probability of distress within the next 24 months. However, our primary 30 days buy-hold-sell recommendation on the company is Strong Buy.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Chimerix. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com